PUBLICATION REGISTRY

Go to research.

Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.

Publikationer som ChEBI hänvisar till för zipalertinib. Visa hela publikationsregistret

A publication hit is not a conclusion. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.

Publications in the selection

12 hits

Bibliografisk träff 2024-10-29

Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity.

Zhao H, Beyett TS, Jiang J, Rana JK, Schaeffner IK, Santana J, Jänne PA, Eck MJ.

Proc Natl Acad Sci U S A · research support, n.i.h., intramural; research-article; journal article · DOI 10.1073/pnas.2417144121

Bibliografisk träff 2024-05-21

Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations.

Thomson C, Barton P, Braybrooke E, Colclough N, Dong Z, Evans L, Floc'h N, Guérot C, Hargreaves D, Khurana P, Li S, Li X, Lister A, McCoull W, McWilliams L, Orme JP, Packer MJ, Swaih AM, Ward RA, Winlow P, Ye Y.

J Med Chem · journal article · DOI 10.1021/acs.jmedchem.4c00227

Bibliografisk träff 2024-01-01

Targeting EGFR Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.

Liu H, Qin J, Qian X.

Cancer Control · review-article; review; journal article · DOI 10.1177/10732748241292782

Bibliografisk träff 2023-11-27

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.

Kobayashi IS, Shaffer W, Viray H, Rangachari D, VanderLaan PA, Kobayashi SS, Costa DB.

JTO Clin Res Rep · brief-report; journal article · DOI 10.1016/j.jtocrr.2023.100614

Bibliografisk träff 2023-09-05

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.

Chen H, Hu S, Patterson AV, Smaill JB, Ding K, Lu X.

J Med Chem · research support, non-u.s. gov't; review; journal article · DOI 10.1021/acs.jmedchem.3c00875

Bibliografisk träff 2023-07-24

Zipalertinib in EGFR Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting.

Aggarwal C, Liu SV.

J Clin Oncol · comment; editorial · DOI 10.1200/jco.23.00958

Bibliografisk träff 2023-06-29

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.

Piotrowska Z, Tan DS, Smit EF, Spira AI, Soo RA, Nguyen D, Lee VH, Yang JC, Velcheti V, Wrangle JM, Socinski MA, Koczywas M, Janik JE, Jones J, Yu HA.

J Clin Oncol · research support, non-u.s. gov't; journal article · DOI 10.1200/jco.23.00152

Bibliografisk träff 2023-01-24

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations.

Kagawa Y, Hayashida T, Liu J, Mori S, Izumi H, Kumagai S, Udagawa H, Hattori N, Goto K, Kobayashi SS.

JTO Clin Res Rep · research-article; journal article · DOI 10.1016/j.jtocrr.2023.100462

Bibliografisk träff 2022-11-15

Targeting exon 20 insertion mutations in lung cancer.

Yang Y, Wang Y.

Curr Opin Oncol · review; journal article · DOI 10.1097/cco.0000000000000919

Bibliografisk träff 2022-07-15

4-Aminopyrazolopyrimidine scaffold and its deformation in the design of tyrosine and serine/threonine kinase inhibitors in medicinal chemistry.

Chen X, Huang Y, Xu W, Cai Y, Yang Y.

RSC Med Chem · review-article; review; journal article · DOI 10.1039/d2md00139j

Bibliografisk träff 2019-08-29

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant EGFR Mutations.

Udagawa H, Hasako S, Ohashi A, Fujioka R, Hakozaki Y, Shibuya M, Abe N, Komori T, Haruma T, Terasaka M, Fujita R, Hashimoto A, Funabashi K, Yasuda H, Miyadera K, Goto K, Costa DB, Kobayashi SS.

Mol Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1541-7786.mcr-19-0419

Bibliografisk träff 2018-05-10

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.

Hasako S, Terasaka M, Abe N, Uno T, Ohsawa H, Hashimoto A, Fujita R, Tanaka K, Okayama T, Wadhwa R, Miyadera K, Aoyagi Y, Yonekura K, Matsuo K.

Mol Cancer Ther · research support, non-u.s. gov't; journal article · DOI 10.1158/1535-7163.mct-17-1206

Go to research.

Publications in the selection

Biochemical analysis of EGFR exon20 insertion variants insASV and insSVD and their inhibitor sensitivity.

Discovery and Optimization of Potent, Efficacious and Selective Inhibitors Targeting EGFR Exon20 Insertion Mutations.

Targeting <i>EGFR</i> Exon 20 Insertion Mutations in Non-small-Cell Lung Cancer: Changes in Treatment Strategies are Coming.

The Impact of On-Target Resistance Mediated by EGFR-T790M or EGFR-C797S on EGFR Exon 20 Insertion Mutation Active Tyrosine Kinase Inhibitors.

Structural Mechanism and Inhibitors Targeting EGFR Exon 20 Insertion (Ex20ins) Mutations.

Zipalertinib in <i>EGFR</i> Exon 20-Mutant Non-Small-Cell Lung Cancer: Drug Development in a Rare but Crowded Setting.

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.

The EGFR C797S Mutation Confers Resistance to a Novel EGFR Inhibitor CLN-081 to EGFR Exon 20 Insertion Mutations.

Targeting exon 20 insertion mutations in lung cancer.

4-Aminopyrazolopyrimidine scaffold and its deformation in the design of tyrosine and serine/threonine kinase inhibitors in medicinal chemistry.

TAS6417/CLN-081 Is a Pan-Mutation-Selective EGFR Tyrosine Kinase Inhibitor with a Broad Spectrum of Preclinical Activity against Clinically Relevant <i>EGFR</i> Mutations.

TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations.